Advertisement

Topics

Merck KGaA, Pfizer's avelumab misses goal in gastric cancer trial

03:19 EST 28 Nov 2017 | Reuters

FRANKFURT (Reuters) - Germany's Merck KGaA said on Tuesday that its cancer immunotherapy avelumab, jointly developed with Pfizer, failed to improve overall survival compared with standard chemotherapy in a late-stage study on gastric cancer patients....

Original Article: Merck KGaA, Pfizer's avelumab misses goal in gastric cancer trial

NEXT ARTICLE

More From BioPortfolio on "Merck KGaA, Pfizer's avelumab misses goal in gastric cancer trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...